期刊文献+

纳米粒作为抗肿瘤药物载体的研究进展 被引量:10

Research progress in nanoparticles as anticancer drug carrier
暂未订购
导出
摘要 纳米粒载药系统可以改变药物的体内分布特征,具有缓控释和靶向给药特性,增加药物的稳定性,提高药物的生物利用度。纳米粒的靶向选择性可以通过增强渗透滞留效应(EPR)、偶联特定的配体,或由于生理条件如pH值、温度等的改变实现。纳米粒可以由多种材料制备并且用于包合各种化学治疗药物以降低药物不良反应,其中,磁性纳米粒作为抗肿瘤药物载体不仅可以用来治疗还能用于成像诊断。本文综述了纳米粒被动靶向、主动靶向、物理化学靶向给药系统用于抗肿瘤药物载体的研究进展。 A nanoparticle drug carrier system that can change the characteristics of drug distribution in vivo has sustained and controlled release features as well as targeted drug delivery. The system can increase the stability of the drug and raise drug bioavailabil- ity. The selective targeting of nanoparticle (NPs) can be achieved through enhanced permeability and retention effect and a conjugated specific ligand or through the effects of physiological conditions, such as pH and temperature. Nanoparticles can be prepared using a wide range of materials and can be used to encapsulate chemotherapeutic agents to reduce toxicity with which the magnetic nanoparti- cles as the anticancer drug carrier can be used for imaging, therapy, and diagnosis. In our study, we reviewed recent progress on nanoparticles as a targeted drug delivery system, including positive-targeting, negative-targeting, and physicochemical-targeting used as anticancer drug carrier.
机构地区 广东药学院
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第6期363-366,共4页 Chinese Journal of Clinical Oncology
基金 广州市重大科技专项计划项目(编号:2008A1-E4101)资助~~
关键词 纳米粒抗肿瘤药物 药物载体 nanoparticles, anticancer drugs, drug carrier
  • 相关文献

参考文献24

  • 1Allen TM, Cullis PR. Drug delivery systems: entering the main- stream [J].Science, 2004, 303(5665):1818-1822.
  • 2Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR--effect[J]. EurJ Pharm Biopharm, 2009, 71 (3) :409-419.
  • 3于莲,崔丹,应晓英,杜永忠.表面修饰脂质纳米粒给药系统的研究进展[J].中国现代应用药学,2011,28(2):108-112. 被引量:14
  • 4Moghimi SM, Hunter AC, Murray JC. Long-circulating and tar- get-specific nanoparticles: theory to practice[J]. Pharmacol Rev, 2001, 53(2):283-318.
  • 5Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PE- Gylated PLGA-based nanoparticles: in vitro and in vivo evaluation [J]. J Control Release, 2009, 133 (1) :11-17.
  • 6刘杰,高福平,唐劲天.肿瘤主动靶向磁性纳米粒子研究现状及其在肿瘤热疗中的应用[J].科技导报,2010,28(19):108-112. 被引量:6
  • 7Lu Y, Low PS. Folate--mediated delivery of macromolecular anticancer therapeutic agents[J]. Adv Drug Deliv Rev, 2002, 54(5):675-693.
  • 8Shen Z, Li Y, Kohama K, et al. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin- nanospheres[J].Pharmacol Res, 2011, 63 (1):51-58.
  • 9Wang X, LiJ, Wang Y, et al. A folate receptor-targeting nanoparti- cle minimizes drug resistance in a human cancer model[J]. ACS Na- no, 2011, 5(8):6184-6194.
  • 10Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer[J]. Curr Opin Chem Biol, 2009, 13 (3):256-262.

二级参考文献57

  • 1郑秀海,董家鸿,李前伟,喻智勇,王曙光.放射性碘标记人工合成RGD肽拮抗物的设计与分子特性的计算机分析与模拟研究[J].第三军医大学学报,2005,27(4):340-342. 被引量:1
  • 2张晓佳,夏强,马全红,段磊,顾宁.高压均质法制备载有维甲酸的纳米结构脂质载体[J].过程工程学报,2005,5(1):54-57. 被引量:7
  • 3刘广元,李前伟,黄定德,刘开元,谢来平,陈杰,罗朝学.^(99)Tc^m-RGD-4CK在动物体内的分布及显像[J].中华核医学杂志,2007,27(1):34-37. 被引量:5
  • 4Delbaldo C, Raymond E, Vera K, et al. Phase Ⅰ and pharmacokinetic study of etaracizumab (Abegrin) , a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors[J]. Invest New Drugs,2008, 26(1):35.
  • 5Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors[J]. Clin Cancer Res, 2010,16(2):699.
  • 6Gao J, Li B, Li H, et al. Development and characterization of a fully functional small anti-HER2 antibody[J].BMB Rep,2009,42(10) :636.
  • 7Goldblatt EM, Lee WH. From bench to bedside: the growing use of translational research in cancer medicine[J].4m J Transl Res,2010,2(1) :1.
  • 8Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase Ⅱ study of the Arbeitsgemeinschaft Intemistische Onkologie (AIO) [J]. Br J Cancer, 2010, 102(3):500.
  • 9Stinchcombe TE, Bradford DS, Hensing TA, et al. A multicenter phase Ⅱ trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer[J]. Cancer Invest , 2010 , 28 ( 2 ) :208.
  • 10Laurent-Puig P, Cayre A, Maneeau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer[J].J Clin Oncol, 2009,27 (35) : 5 924.

共引文献48

同被引文献113

引证文献10

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部